SOPHORA JAPONICA TINCTURE

Ukraine

The drug is used to treat purulent inflammatory processes, such as wounds and trophic ulcers.

Brand name SOPHORA JAPONICA TINCTURE
Dosage form tincture
Active substance / Dosage
Prescription type over-the-counter (OTC)
ATC code
Registration number UA/8445/01/01
Manufacturer PJSC "Fitofarm"
SOPHORA JAPONICA TINCTURE tincture

Frequently asked questions

How should Sophora japonica tincture be used correctly?

Adults and children aged 12 and older should apply the tincture externally: by irrigation or by applying applications under a bandage. The duration of the course depends on the form and severity of the disease.

What side effects may occur from using the drug?

Allergic reactions are possible, including itching, skin rash, or redness.

Who should not use this product?

The drug should not be used in cases of individual hypersensitivity to it, nor in children under 12 years of age.

Can the tincture be used by pregnant or breastfeeding women?

Due to the ethanol content in its composition, the use of the tincture is not recommended for pregnant women and women during the breastfeeding period.

Does the drug affect the ability to drive a car?

The drug does not affect reaction speed or the ability to drive a vehicle or engage in activities that require high concentration.

Instructions for use

Table of contents

INSTRUCTION FOR MEDICAL USE OF THE MEDICINAL PRODUCT SOFORA JAPANESE TINCTURE

Composition:
Active substance: crushed fruit tincture of Japanese sophora (Fructus Sophorae japonicae);
1 bottle contains 40 ml of crushed fruit tincture of Japanese sophora (Fructus Sophorae japonicae) (1 : 2) (extractant – ethanol 48%).

Medicinal form. Tincture.

Main physicochemical properties: Transparent brown liquid with a characteristic odor. Sediment may occur during storage.

Pharmacotherapeutic group. Antiseptics and disinfectants.
ATC code: D08AX.

Pharmacological properties. Biologically active substances contained in the fruits of Japanese sophora (rutin, sophoroside, genistein, kaempferol, quercetin, and other compounds) determine the anti-inflammatory, antimicrobial, and trophic effects of the preparation, strengthen blood vessel walls, and reduce their fragility.

Clinical characteristics.

Indications. Purulent inflammatory conditions (wounds, trophic ulcers).

Contraindications. Individual hypersensitivity to the drug.

Interaction with other medicinal products and other forms of interaction. Unknown.

Special precautions for use.

Use during pregnancy or breastfeeding. Since the preparation contains ethanol, it is not recommended for use in pregnant women and women during breastfeeding.

Ability to influence reaction rate when driving vehicles or operating machinery. The drug does not affect the ability to drive vehicles or engage in other activities requiring increased attention and psychomotor reaction speed.

Method and dosage of administration. For external use in adults and children aged 12 years and older in wound conditions as applications under a dressing or as sprays.
The duration of treatment depends on the form and severity of the disease, the effectiveness of the drug, and the type of therapy (monotherapy or combination therapy with other medicinal products).

Children. Not to be used in children under 12 years of age.

Overdose. Not established.

Adverse effects.

Allergic reactions (including redness, skin rash, itching).

Shelf life. 2 years.

Storage conditions. Store in the original packaging at a temperature not exceeding 25 °C. Keep out of reach of children.

Packaging. 40 ml in bottles.

Release category. Over-the-counter.

Manufacturer. JSC "FITOFARM".
Location and address of manufacturer’s place of business:
2 Sybirtseva St., Bakhmut, Donetsk region, 84500, Ukraine.

Marketing authorization holder. JSC "FITOFARM".
Address of the marketing authorization holder:
12 Almatinska St., Kyiv, 02092, Ukraine.

Similar drugs

The original data is available in the language of the country of manufacture.

Data source: State Register of Medicinal Products of Ukraine

Data last verified: August 13, 2026